African Regional IP Organization (ARIPO): These 4 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

Generic name: peginesatide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2023
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,042
Patent Title: Novel peptides that bind to the erythropoietin receptor

OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-four countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Generic name: lenalidomide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 04, 2023
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,324
Patent Title: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione.

REVLIMID is a drug marketed by Celgene. There are fifteen patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has three hundred and seventy-seven patent family members in forty-one countries. There has been litigation on patents covering REVLIMID

See drug price trends for REVLIMID.

The generic ingredient in REVLIMID is lenalidomide. There are fourteen drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the lenalidomide profile page.

Generic name: umeclidinium bromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,213
Patent Title: Muscarinic acetylcholine receptor antagonists.

INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

Generic name: dacomitinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,204
Patent Title: 4-phenylamino-quinazolin-6-yl-amides.

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety patent family members in forty-seven countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.